A consortium led by the GCS (Health Cooperation Group) Nantes-Angers Regional Institute of Cancer Research
The SIRIC ILIAD (Imaging and Longitudinal Investigations to Ameliorate Decision-making) is a multidisciplinary regional consortium of 10 partners, bringing together health establishments, research laboratories, universities, prestigious schools and technopolis.
Led by the Health Cooperation Group (GCS) IRéCAN (Nantes-Angers Regional Institute of Cancer Research), the SIRIC ILIAD brings together expertise in medicine, biology, bioinformatics, mathematics, epidemiology and human sciences.
The CHU of Nantes
Being number 1 regional health establishment, the CHU of Nantes has a full support system for major hematological and solid tumours affecting adults and children. More than twenty specialised services provide their medical and scientific expertise to the cancer activity. The CHU of Nantes thus ensures comprehensive cancer management : prevention, diagnosis, treatment, support care and accompaniment.
The CHU of Nantes is known as :
for early-phase clinical trials in hematology in France
according to numbers of patients with multiple myeloma being cared for
in nuclear oncology
thanks to the clinical unit and ARRONAX Cyclotron, unique in Europe and shared with the ICO
Beyond their mission of care, the CHU of Nantes also carries out teaching and research missions. Their policy of extremely proactive biomedical research is recognised nationally and has allowed them to be one of the ten « strong research » CHUs today. The research at the CHU is characterised by their partnerships with the University of Nantes and with Inserm. The CHU of Nantes is also the founder of the NExT I-site.
The CHU of Nantes is the number 1 centre in France and 4th in Europe in terms of publications about multiple myeloma.
Born from the fusion of the cancer research centres of Angers (Paul Papin) and Nantes (René Gauducheau) in January 2011, the ICO is one of the 18 Cancer Control Centres (CLCC) in France, regrouped under the aegis of UNICANCER. The ICO is the number 1 Cancer Control Centre in the provinces by the number of patients cared for.
The ICO is known as :
according to numbers of patients with breast cancer being cared for
in nuclear oncology
thanks to the clinical unit and ARRONAX Cyclotron, unique in Europe and shared with the CHU in Nantes
French surgical Centre
for breast reconstruction
The ICO is the number 1 Cancer Control Centre in the provinces by the number of patients cared for and the number 1 French Centre in terms of radiotherapy technological platforms.
Being the Fourth Centre in France in terms of clinical trials, the ICO also includes numerous installations for clinical and translational research, as well as multiples links with the INSERM / CNRS units for the development of fundamental and translational research.
The ICO is number 2 in terms of publications on breast cancer.
The CHU of Angers
Being the number 2 university hospital in the Pays de la Loire, the CHU of Angers offers support for hematological and solid tumours affecting adults and children.
Clinical hematology, bronchial cancers and digestive oncology represent nearly 60 % of the cancer activity at the CHU of Angers.
The research teams in Angers are recognised and made available to the ILIAD project, through the work of Pr Yves Roquelaure, with unique expertise in the area of return to work after cancer.
for return to work after chronic illnesses
The members of SIRIC
A public establishment for health with a scientific and technological character, the Inserm depends on both the Ministry of Health and the Ministry of Research. Nationally, Inserm has 15,000 collaborators divided into 12 regional delegations and 9 thematic institutes of whom the work has the aim of improving knowledge about life and disease, therapeutic innovation, and research into public health. Three Inserm units, represented by the Wider West Regional Delegation, are members of SIRIC : the CRCINA, the IRSET and the SPHERE laboratory.
The Arronax GIP
The Arronax Public Interest Group (GIP) was created in 2008 to support the functioning of the cyclotron-type accelerator Arronax (Accelerator in Research into Radiochemistry and Oncology in Nantes Atlantique), unique in the world with its characteristics and its mission to support medical research and, more specifically, nuclear medicine. With its allocation of a 4-million-euro budget, the Arronax GIP also manages the ArronaxPlus Equipex. The members of the Arronax GIP are the CNRS, Inserm, the University of Nantes, the Mines Telecom Institute, the CHU of Nantes, the ICO, the Ministry of Research (MESR) and the Pays de la Loire Regional Council.
Being a multidisciplinary University, the University of Nantes brings together 20 academic components, an engineering school and a Sciences of the Universe Observatory as well as 54 accredited research units. In terms of training, it hosts more than half the students of the Pays de la Loire region and it welcomes nearly 4,000 foreign students every year. Its excellence in fundamental and translational oncological research is widely recognised through its “investments in the future” programmes dedicated to the development of innovative immunotherapies (IGO LabEX) and novel radiopharmaceutical products (IRON LabEX and ArronaxPlus Equipex). Oncology, nuclear medicine, and precision medicine are also at the heart of the topic « health of the future » led by the NExT I-Site.
The University of Angers
The University of Angers offers six master’s programmes in the field of health sciences (Physiopathology and vascular pharmacology, Cell interactions and therapeutic applications, Cellular and molecular neurobiology, Signals and images in biology and medicine, modelling in clinical and epidemiological pharmacology and Man-imal (Engineering and Management of Health and Nutritional Safety around the Triptych Animal – Human – Food) ). The medical faculty of Angers holds a research summer school every year for international students, including several workshops on cancer research run by international researchers. An international programme is proposed to 3rd-year medical students with modules in immunology, genetics and physiopathology completed with a research work placement.
Ecole Centrale of Nantes
Centrale Nantes (ECN) is a prestigious engineering school ranked among the top 10 French engineering establishments and fully recognised by respected national, European, and international institutions , in particular through its Erasmus Mundus master’s. The ECN consists of 6 research laboratories ( most under co-supervision with the CNRS and / or the University of Nantes ) and 550 researchers. Wholeheartedly involved in research into health, the Ecole Centrale of Nantes offers 6 world class master’s in science, technology, and health and 4 master’s which are certified Erasmus Mundus. The specialisations in health sciences cover different areas (analysis of data and applications for processing signals and images, informatics, mathematics and applications, mechanical modelling and simulation, virtual reality, processing of neuronal signals, analysis of genomic data, modelling of biological networks, automation of hospital equipment) and involve about twenty researchers.
The Pays de la Loire Epidemiology of Cancers Association (EPIC-PL)
The cancers registry is represented by the EPIC-PL association. They have a double function in public health (producing descriptive indicators of the epidemiology of cancers: incidence, survival) and research ( carrying out studies, possibly after being commissioned by local and national partners or public bodies: evaluating organised screening programmes, studying cancer management practices and factors of social inequality, researching factors of risk …).
The EPIC-PL association participates in the epidemiological monitoring of cancers, both locally and nationally, within the framework of the French network of cancer registries (FRANCIM) ; the association is the leader in research into breast cancer in this network and coordinates several national and international projects in breast cancer.
Technopolis of the Pays de la Loire region, Atlanpole consists of 500 companies, 70 research and higher education institutes, and 25 innovation structures and platforms. Atlanpole encourages the emergence, creation, and development of innovative companies. Being a key player which supports collaborative projects, Atlanpole is a partner of several competitiveness clusters including the « Image and Networks » digital hub and it also pilots Atlanpole Biotherapies, dedicated to national and international collaborative R&D development projects in immunobiotherapies, personalised medicine and radiopharmaceuticals.